Grace Therapeutics, Inc. (GRCE)Healthcare | Biotechnology | Princeton, United States | NasdaqCM
1.99 USD
-0.03
(-1.485%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 2.00 +0.01 (0.503%) ⇧ (Oct. 13, 2026, 5:01 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 3:44 a.m. EDT
Grace Therapeutics presents a high-risk profile driven by deteriorating fundamentals and a lack of capital preservation mechanisms. The company is burning cash aggressively with negative free cash flow and negative returns on equity, while trading at a significant discount to its book value—a common characteristic of distressed biotech firms awaiting a catalyst. The absence of any dividend yield eliminates income as a buffer against volatility. While the stock trades below its 52-week high, the recent news of an FDA rejection for a key drug and a manufacturing setback suggests the worst-case scenario is being priced in, yet the path to profitability remains unclear. Options data confirms this fear, with traders buying insurance against further drops rather than betting on a recovery. Without a confirmed clinical success or a clear route to profitability, the business quality is currently insufficient to justify a long-term hold, making this a speculative vehicle best avoided by investors seeking stability. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.086585 |
| AutoETS | 0.089041 |
| AutoTheta | 0.102351 |
| MSTL | 0.102645 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.80 |
| Ljung-Box p | 0.001 |
| Jarque-Bera p | 0.010 |
| Excess Kurtosis | 0.64 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 41,861,500 |
| Forward P/E | -4.44 |
| Beta | 0.33 |
| Previous Name | Acasti Pharma Inc. |
| Website | https://www.gracetx.com |
As of Oct. 10, 2026, 3:44 a.m. EDT: Speculators are positioning exclusively for downside protection with heavy put volume and open interest at strikes below the current price, while call activity is negligible. Implied volatility is significantly elevated for puts compared to calls, indicating a market consensus focused on potential further declines rather than rallies.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.32890368 |
| Address1 | 103 Carnegie Center |
| Address2 | Suite 300 |
| All Time High | 2,016.0 |
| All Time Low | 1.72 |
| Ask | 2.54 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 101,830 |
| Average Daily Volume3 Month | 167,031 |
| Average Volume | 167,031 |
| Average Volume10Days | 101,830 |
| Beta | 0.333 |
| Bid | 1.54 |
| Bid Size | 2 |
| Book Value | 2.962 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.99 |
| Current Ratio | 11.466 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.02 |
| Day Low | 1.965 |
| Display Name | Grace Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,750,419,000 |
| Earnings Timestamp Start | 1,750,419,000 |
| Ebitda | -10,364,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.712 |
| Enterprise Value | 28,105,500 |
| Eps Current Year | -0.763 |
| Eps Forward | -0.44813505 |
| Eps Trailing Twelve Months | -1.17 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.132 |
| Fifty Day Average Change | -0.14199996 |
| Fifty Day Average Change Percent | -0.06660411 |
| Fifty Two Week Change Percent | -32.890366 |
| Fifty Two Week High | 5.18 |
| Fifty Two Week High Change | -3.1899998 |
| Fifty Two Week High Change Percent | -0.6158301 |
| Fifty Two Week Low | 1.79 |
| Fifty Two Week Low Change | 0.20000005 |
| Fifty Two Week Low Change Percent | 0.11173187 |
| Fifty Two Week Range | 1.79 - 5.18 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,328,625,000,000 |
| Float Shares | 13,467,202 |
| Forward Eps | -0.44813505 |
| Forward P E | -4.4406257 |
| Free Cashflow | -6,995,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Fullday Change | -0.01999998 |
| Fullday Change Percent | -0.99009806 |
| Fullday Price | 1.99 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18675 |
| Held Percent Institutions | 0.31513 |
| Implied Shares Outstanding | 21,035,930 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,774,915,200 |
| Last Split Date | 1,688,947,200 |
| Last Split Factor | 1:6 |
| Long Business Summary | Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. |
| Long Name | Grace Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 41,861,500 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_47663822 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-13 |
| Net Income To Common | -20,221,000 |
| Next Fiscal Year End | 1,806,451,200 |
| Non Diluted Market Cap | 44,806,530 |
| Number Of Analyst Opinions | 2 |
| Open | 2.0 |
| Operating Cashflow | -10,289,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 609 322 1602 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.5025121 |
| Post Market Price | 2.0 |
| Post Market Time | 1,791,925,286 |
| Prev Name | Acasti Pharma Inc. |
| Previous Close | 2.02 |
| Price Eps Current Year | -2.6081257 |
| Price Hint | 4 |
| Price To Book | 0.67184335 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.021 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.03 |
| Regular Market Change Percent | -1.48515 |
| Regular Market Day High | 2.02 |
| Regular Market Day Low | 1.965 |
| Regular Market Day Range | 1.965 - 2.02 |
| Regular Market Open | 2.0 |
| Regular Market Previous Close | 2.02 |
| Regular Market Price | 1.99 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 49,222 |
| Return On Assets | -0.10814 |
| Return On Equity | -0.36186 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 21,035,930 |
| Shares Percent Shares Out | 0.08180001 |
| Shares Short | 1,721,067 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,586,005 |
| Short Name | Grace Therapeutics, Inc. |
| Short Percent Of Float | 0.0945 |
| Short Ratio | 11.82 |
| Source Interval | 15 |
| State | NJ |
| Symbol | GRCE |
| Target High Price | 7.8384447 |
| Target Low Price | 3.9051447 |
| Target Mean Price | 5.8717947 |
| Target Median Price | 5.8717947 |
| Total Cash | 13,756,000 |
| Total Cash Per Share | 0.654 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.17 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.93295 |
| Two Hundred Day Average Change | -0.94295 |
| Two Hundred Day Average Change Percent | -0.32150224 |
| Type Disp | Equity |
| Volume | 49,222 |
| Website | https://www.gracetx.com |
| Zip | 8,540 |